Literature DB >> 22718454

[Central venous catheter lock to prevent thrombosis and bacterial infection].

Salvatore Mandolfo1.   

Abstract

The permanent central venous catheter (CVCp) for vascular access is increasingly common in patients on hemodialysis. The main problem related to CVCp is the biofilm, which leads to malfunction and an increased risk of infections. In recent years lock solutions for the CVCp have become popular. Heparin should be abandoned because it induces rapid biofilm development and exposes the patient to the risk of bleeding due to overspill of heparin into the bloodstream. Citrate solution (3.8%) is associated with the best risk/benefit ratio for CVC functioning but offers no advantages in terms of reducing infections. The use of hypertonic citrate (46.7%) or antimicrobic solutions (AML) should be reserved for patients with a high incidence of infection and in cases where it is not possible to replace the CVCp. AML should be used for short periods only because of the risk of the development of resistance. The results of ongoing trials will be needed to establish the usefulness of the solution with ethanol. In the correct management of the CVCp, whichever lock solution is used, continuing staff training and widespread application of hygiene measures is of the utmost importance.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22718454

Source DB:  PubMed          Journal:  G Ital Nefrol        ISSN: 0393-5590


  2 in total

1.  In Vitro and In Vivo Activity of a Novel Catheter Lock Solution against Bacterial and Fungal Biofilms.

Authors:  J Chandra; L Long; N Isham; P K Mukherjee; G DiSciullo; K Appelt; M A Ghannoum
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

2.  Anticoagulant therapies versus heparin for the prevention of hemodialysis catheter-related complications: systematic review and meta-analysis of prospective randomized controlled trials.

Authors:  Jinrui Liu; Chang'an Wang; Hongfei Zhao; Jinghua Zhang; Jie Ma; Yuanyuan Hou; Hongbin Zou
Journal:  Int J Clin Exp Med       Date:  2015-08-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.